See more : Shanghai Chicmax Cosmetic Co., Ltd. (2145.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Humanigen, Inc. (HGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humanigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Burgundy Technology Acquisition Corporation (BTAQ) Income Statement Analysis – Financial Results
- HY Energy Group Co.,Ltd (600387.SS) Income Statement Analysis – Financial Results
- Artificial Intelligence Technology Solutions Inc. (AITX) Income Statement Analysis – Financial Results
- The Central and Eastern Europe Fund, Inc. (CEE) Income Statement Analysis – Financial Results
- RemeGen Co., Ltd. (REGMF) Income Statement Analysis – Financial Results
Humanigen, Inc. (HGEN)
About Humanigen, Inc.
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 55.21M | 213.12M | 72.71M | 2.62M | 2.22M | 11.17M | 10.45M | 16.72M | 26.57M | 32.64M | 24.52M | 18.51M | 18.89M | 22.86M |
| General & Administrative | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Other Expenses | 0.00 | -1.61M | -1.00K | -1.00K | 324.00K | 431.00K | 125.00K | -213.00K | -154.00K | -39.00K | 113.00K | -8.00K | 915.00K | 348.00K |
| Operating Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Cost & Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 88.00K | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.92M | 2.26M | 1.34M | 1.35M | 852.00K | 3.06M | 131.00K | 842.00K | 1.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 492.00K | -1.61M | -1.00K | -1.00K | 19.00K | 48.00K | 102.00K | 197.00K | 310.00K | 298.00K | 304.00K | 595.00K | 843.00K | 844.00K |
| EBITDA | -67.81M | -234.39M | -88.20M | -8.95M | -10.99M | -18.55M | -18.60M | -31.00M | -36.47M | -40.56M | -23.18M | -1.67M | -5.28M | -26.62M |
| EBITDA Ratio | -2,697.37% | -6,519.75% | -28,268.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,190.91% | -380.09% | -8.25% | -29.81% | -4,519.35% |
| Operating Income | -68.30M | -232.77M | -88.20M | -8.94M | -11.33M | -19.03M | -18.83M | -34.35M | -36.72M | -40.91M | -23.48M | -2.27M | -6.12M | -27.46M |
| Operating Income Ratio | -2,716.95% | -6,474.88% | -28,268.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,975.00% | -385.08% | -11.19% | -34.57% | -4,662.65% |
| Total Other Income/Expenses | -2.43M | -3.88M | -1.34M | -1.35M | -673.00K | -2.96M | -8.19M | -1.03M | -1.28M | -1.04M | -27.00K | 35.00K | 1.02M | 639.00K |
| Income Before Tax | -70.73M | -236.65M | -89.54M | -10.29M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.82M |
| Income Before Tax Ratio | -2,813.44% | -6,582.73% | -28,697.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,554.16% |
| Income Tax Expense | -492.00K | 2.26M | 1.34M | 1.35M | 179.00K | 3.49M | 256.00K | 629.00K | 1.06M | 1.05M | 140.00K | -43.00K | -108.00K | -19.00K |
| Net Income | -70.24M | -238.91M | -90.87M | -11.64M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.81M |
| Net Income Ratio | -2,793.87% | -6,645.70% | -29,125.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,550.93% |
| EPS | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| EPS Diluted | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| Weighted Avg Shares Out | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
| Weighted Avg Shares Out (Dil) | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
EQUITY ALERT: Rosen Law Firm Encourages Humanigen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – HGEN
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
Why Is Humanigen (HGEN) Stock Down 16% Today?
Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates
Humanigen Reports Second Quarter 2022 Financial Results
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm
HGEN Alert: Johnson Fistel, Globally-Recognized Law Firm, Investigates Humanigen
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
HC Wainwright Downgrades Humanigen On Disappointing COVID-19 Study - What's Next
Source: https://incomestatements.info
Category: Stock Reports